Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer.

Damaraju S, Murray D, Dufour J, Carandang D, Myrehaug S, Fallone G, Field C, Greiner R, Hanson J, Cass CE, Parliament M.

Clin Cancer Res. 2006 Apr 15;12(8):2545-54.

2.

Association of a XRCC3 polymorphism and rectum mean dose with the risk of acute radio-induced gastrointestinal toxicity in prostate cancer patients.

Fachal L, Gómez-Caamaño A, Peleteiro P, Carballo A, Calvo-Crespo P, Sánchez-García M, Lobato-Busto R, Carracedo A, Vega A.

Radiother Oncol. 2012 Dec;105(3):321-8. doi: 10.1016/j.radonc.2012.09.013. Epub 2012 Oct 15.

PMID:
23075580
3.

Correlation between acute and late toxicity in 973 prostate cancer patients treated with three-dimensional conformal external beam radiotherapy.

Jereczek-Fossa BA, Zerini D, Fodor C, Santoro L, Serafini F, Cambria R, Vavassori A, Cattani F, Garibaldi C, Gherardi F, Ferrari A, Rocco B, Scardino E, de Cobelli O, Orecchia R.

Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):26-34. doi: 10.1016/j.ijrobp.2009.07.1742. Epub 2010 Feb 3.

PMID:
20133085
4.
5.

Single nucleotide polymorphisms in DNA repair genes as risk factors associated to prostate cancer progression.

Henríquez-Hernández LA, Valenciano A, Foro-Arnalot P, Álvarez-Cubero MJ, Cozar JM, Suárez-Novo JF, Castells-Esteve M, Fernández-Gonzalo P, De-Paula-Carranza B, Ferrer M, Guedea F, Sancho-Pardo G, Craven-Bartle J, Ortiz-Gordillo MJ, Cabrera-Roldán P, Herrera-Ramos E, Rodríguez-Gallego C, Rodríguez-Melcón JI, Lara PC.

BMC Med Genet. 2014 Dec 24;15:143. doi: 10.1186/s12881-014-0143-0.

6.

The evolution of rectal and urinary toxicity and immune response in prostate cancer patients treated with two three-dimensional conformal radiotherapy techniques.

Vranova J, Vinakurau S, Richter J, Starec M, Fiserova A, Rosina J.

Radiat Oncol. 2011 Jul 27;6:87. doi: 10.1186/1748-717X-6-87.

7.

Association between single nucleotide polymorphisms in the gene for XRCC1 and radiation-induced late toxicity in prostate cancer patients.

Langsenlehner T, Renner W, Gerger A, Hofmann G, Thurner EM, Kapp KS, Langsenlehner U.

Radiother Oncol. 2011 Mar;98(3):387-93. doi: 10.1016/j.radonc.2011.01.021. Epub 2011 Feb 21.

PMID:
21345510
8.

Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity.

Vargas C, Yan D, Kestin LL, Krauss D, Lockman DM, Brabbins DS, Martinez AA.

Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):141-9.

PMID:
16111582
9.

Short-course, intensity-modulated radiotherapy for localized prostate cancer.

Kupelian PA, Willoughby TR.

Cancer J. 2001 Sep-Oct;7(5):421-6.

PMID:
11693901
10.

Gastro-intestinal and genito-urinary morbidity after 3D conformal radiotherapy of prostate cancer: observations of a randomized trial.

Koper PC, Jansen P, van Putten W, van Os M, Wijnmaalen AJ, Lebesque JV, Levendag PC.

Radiother Oncol. 2004 Oct;73(1):1-9.

PMID:
15465140
11.

Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer.

Burri RJ, Stock RG, Cesaretti JA, Atencio DP, Peters S, Peters CA, Fan G, Stone NN, Ostrer H, Rosenstein BS.

Radiat Res. 2008 Jul;170(1):49-59. doi: 10.1667/RR1219.1.

PMID:
18582155
12.

Dose-volume relationship for acute side effects during high dose conformal radiotherapy for prostate cancer.

Nuyttens JJ, Milito S, Rust PF, Turrisi AT 3rd.

Radiother Oncol. 2002 Aug;64(2):209-14.

PMID:
12242132
13.

[Acute toxicity in 50 patients with prostate cancer treated with conformal radiation therapy].

Nasr E, Merhej S, Nehme Nasr D, Fares G.

J Med Liban. 2001 Nov-Dec;49(6):325-8. French.

PMID:
12744634
14.

Trade-off to low-grade toxicity with conformal radiation therapy for prostate cancer on Radiation Therapy Oncology Group 9406.

Michalski JM, Winter K, Purdy JA, Wilder R, Perez CA, Roach M, Parliament M, Pollack A, Markoe A, Harms WB, Sandler H, Cox JD.

Semin Radiat Oncol. 2002 Jan;12(1 Suppl 1):75-80.

PMID:
11917289
15.

Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.

Michalski JM, Winter K, Purdy JA, Parliament M, Wong H, Perez CA, Roach M, Bosch W, Cox JD.

Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):706-13.

PMID:
15936549
16.

Acute toxicity after image-guided intensity modulated radiation therapy compared to 3D conformal radiation therapy in prostate cancer patients.

Wortel RC, Incrocci L, Pos FJ, Lebesque JV, Witte MG, van der Heide UA, van Herk M, Heemsbergen WD.

Int J Radiat Oncol Biol Phys. 2015 Mar 15;91(4):737-44. doi: 10.1016/j.ijrobp.2014.12.017.

PMID:
25752386
17.
18.

Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer.

Peeters ST, Hoogeman MS, Heemsbergen WD, Slot A, Tabak H, Koper PC, Lebesque JV.

Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1142-52. Epub 2005 Jun 4.

PMID:
15939547
19.

Supplemental Content

Support Center